Clinical Trial Update: Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 adjuvant trial evaluating nimotuzumab with nab-paclitaxel and gemcitabine in EGFR-positive resectable pancreatic cancer. The study is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Zhejiang Provincial People's Hospital | Conditions: Pancreatic Cancer Resectable | Phase 2 | Status: RECRUITING